Analysts Anticipate Odonate Therapeutics Inc (ODT) to Announce -$0.88 Earnings Per Share

Share on StockTwits

Equities analysts predict that Odonate Therapeutics Inc (NASDAQ:ODT) will post ($0.88) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Odonate Therapeutics’ earnings. The company is scheduled to issue its next quarterly earnings report on Monday, October 29th.

On average, analysts expect that Odonate Therapeutics will report full-year earnings of ($3.43) per share for the current fiscal year, with EPS estimates ranging from ($3.53) to ($3.32). For the next year, analysts expect that the company will post earnings of ($3.39) per share, with EPS estimates ranging from ($3.47) to ($3.30). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Odonate Therapeutics.

Odonate Therapeutics (NASDAQ:ODT) last released its quarterly earnings results on Monday, July 30th. The company reported ($0.79) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.82) by $0.03.

Separately, Zacks Investment Research upgraded Odonate Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a research note on Wednesday, May 23rd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Odonate Therapeutics presently has an average rating of “Hold” and a consensus price target of $31.00.

In other news, CEO Kevin C. Tang bought 49,685 shares of the firm’s stock in a transaction that occurred on Monday, August 20th. The stock was purchased at an average cost of $19.49 per share, with a total value of $968,360.65. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin C. Tang bought 22,810 shares of the firm’s stock in a transaction that occurred on Wednesday, August 15th. The stock was purchased at an average cost of $18.93 per share, with a total value of $431,793.30. The disclosure for this purchase can be found here. Insiders own 49.00% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in ODT. Schwab Charles Investment Management Inc. raised its stake in shares of Odonate Therapeutics by 19.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 34,137 shares of the company’s stock worth $754,000 after buying an additional 5,601 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in Odonate Therapeutics during the first quarter valued at about $128,000. California State Teachers Retirement System purchased a new position in Odonate Therapeutics during the first quarter valued at approximately $218,000. Redmile Group LLC boosted its stake in Odonate Therapeutics by 2.8% during the second quarter. Redmile Group LLC now owns 610,600 shares of the company’s stock worth $13,482,000 after buying an additional 16,400 shares during the last quarter. Finally, Alps Advisors Inc. acquired a new position in Odonate Therapeutics during the second quarter worth $862,000. 86.90% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:ODT traded up $0.37 during trading on Thursday, hitting $19.13. The stock had a trading volume of 38,391 shares, compared to its average volume of 35,650. Odonate Therapeutics has a 12-month low of $15.15 and a 12-month high of $32.00.

Odonate Therapeutics Company Profile

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.

See Also: Fiduciary

Get a free copy of the Zacks research report on Odonate Therapeutics (ODT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply